Compare Cytokinetics Inc (CYTK) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Banco Santander SA — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Banco Santander SA trades at $14.85 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 19.9× Cytokinetics Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SAN | |
|---|---|---|
Market Cap | $10.63B | $211.63B |
Sector | Technology | Financials |
52-Week High | $87.26 | $14.71 |
52-Week Low | $34.31 | $9.37 |
Enterprise Value | $10.74B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Banco Santander (SAN) trades at $14.83, up 0.92% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, beating estimates in Q1 but missing in Q2, while net income grew to $14.10 billion in 2025. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, enhancing its U.S. footprint.
Outlook is supported by analyst consensus (64% buy ratings) and record profitability, but risks include volatile earnings, high debt levels, and integration challenges from acquisitions. The stock's valuation appears reasonable with a P/E of 14.4, offering potential for growth if execution remains strong amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
